AlQahtani, 103 patient HCQ late treatment RCT: 4% improved recovery [p=0.94] and 47% improved viral clearance [p=0.13] https://c19p.org/alqahtani2
copied to clipboard
Randomized controlled trial of favipiravir, hydroxychloroquine, and standard care in patients with mild/moderate COVID-19 disease
et al., Scientific Reports, doi:10.1038/s41598-022-08794-w, NCT04387760 (history)
RCT with 54 favipiravir, 51 HCQ, and 52 SOC hospitalized patients in Bahrain, showing no significant differences. Viral clearance improved with both treatments, but did not reach statistical significance with the small sample size.
|
risk of ICU admission, 23.5% lower, RR 0.76, p = 1.00, treatment 3 of 51 (5.9%), control 4 of 52 (7.7%), NNT 55.
|
|
risk of no recovery, 4.1% lower, RR 0.96, p = 0.94, treatment 5 of 49 (10.2%), control 5 of 47 (10.6%), NNT 230.
|
|
risk of no viral clearance, 47.4% lower, RR 0.53, p = 0.13, treatment 7 of 38 (18.4%), control 14 of 40 (35.0%), NNT 6.0.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
AlQahtani et al., 23 Mar 2022, Randomized Controlled Trial, Bahrain, peer-reviewed, 13 authors, study period August 2020 - March 2021, trial NCT04387760 (history).
Late treatment
is less effective
is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.